January 28, 2014Open Access

Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

TTC influenced survival outcomes in the overall study cohort. This finding was particularly meaningful for patients with stage III BC, TNBC, and trastuzumab-treated HER2-positive tumors who experienced worse outcomes when chemotherapy was delayed. Our findings suggest that early initiation of chemotherapy should be granted for patients in these high-risk groups.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Gagliato et al. (Tue,) studied this question.

synapsesocial.com/papers/69cfb6a7ca738d6973cde851 https://doi.org/https://doi.org/10.1200/jco.2013.49.7693

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Status of breast cancer prognostication based on histopathologic data.1994 · 55 citations
2Simple Procedures Can Markedly Enhance Automated Immunoassay Performance1994 · 23 citations
3The epidemiology of triple-negative breast cancer, including race2009 · 340 citations
4<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy2006 · 508 citations
5Clinicopathological features and treatment strategy for triple-negative breast cancer2010 · 51 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo